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Hormone systemEPA’s Endocrine Disruptor Screening Program Tier 1 battery consists of eleven assays intended to identify
the potential of a chemical to interact with the estrogen, androgen, thyroid, or steroidogenesis systems.
We have collected control data from a subset of test order recipients from the ﬁrst round of screening.
The analysis undertaken herein demonstrates that the EPA should review all testing methods prior to
issuing further test orders. Given the frequency with which certain performance criteria were violated,
a primary focus of that review should consider adjustments to these standards to better reﬂect biological
variability. A second focus should be to provide detailed, assay-speciﬁc direction on when results should
be discarded; no clear guidance exists on the degree to which assays need to be re-run for failing to meet
performance criteria. A third focus should be to identify permissible differences in study design and exe-
cution that have a large inﬂuence on endpoint variance. Experimental guidelines could then be re-deﬁned
such that endpoint variances are reduced and performance criteria are violated less frequently. It must be
emphasized that because we were restricted to a subset (approximately half) of the control data, our
analyses serve only as examples to underscore the importance of a detailed, rigorous, and comprehensive
evaluation of the performance of the battery.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Section 408(p) of the 1996 Food Quality Protection Act (FQPA)
(US EPA, 1996) mandated the US Environmental Protection
Agency (EPA) to develop and maintain a screening program to
investigate the potential of chemicals to interfere with the endo-
crine system in humans. After passage of the FQPA, EPA convened
a federal advisory committee, the Endocrine Disruptor Screening
and Testing Advisory Committee (EDSTAC), to assess the current
state-of-the-science and assist in developing an endocrine screen-
ing program (The Keystone Center, 1996). EDSTAC concluded that
the assays needed to evaluate endocrine activity varied signiﬁ-
cantly in their degree of development and recommended that
EPA: (1) adopt a two-tiered, hierarchical testing and evaluationframework; and (2) initiate a research program to develop, stan-
dardize, and validate the necessary assays (EDSTAC, 1998).
Based largely on the EDSTAC recommendation, EPA developed a
two-tiered framework for the Endocrine Disruptor Screening
Program (EDSP). The EDSP Tier 1 Endocrine Screening Battery
(EDSP ESB) consists of eleven assays (ﬁve in vitro and six in vivo)
intended to identify the potential of a chemical to interact with
the estrogen, androgen, thyroid, or steroidogenesis systems in
humans and wildlife. EDSP Tier 2 testing is designed to identify
and establish a quantitative, dose–response relationship for any
adverse effects that might result from interactions with the endo-
crine system. Thus, the purpose of the EDSP ESB is to differentiate
chemicals with the potential to interact from those that have little
or no such potential. EPA intends to use a weight-of-evidence
approach to make this determination (Borgert et al. 2011a; US
EPA, 2011a).
EPA began issuing the ﬁrst set of test orders for the EDSP in
2009. Following the recommendation of a joint committee of the
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(SAB/SAP) to initially screen 50–100 chemicals (US EPA, 1999),
EPA has elected to proceed in phases, with the ﬁrst phase com-
posed of 67 chemicals (hereafter, List 1) (US EPA, 2009a).
Recognizing that many of the eleven EDSP ESB assays had not been
fully validated, the SAB/SAP also recommended that EPA review all
testing methods once data were collected from the initial 50 to 100
chemicals (US EPA, 1999). Indeed, any evaluation leading to Tier 2
testing would be premature until the battery has been thoroughly
evaluated (Borgert et al., 2011b).
EPA has required manufacturers and importers of List 1 chemi-
cals to conduct the EDSP ESB in accordance with speciﬁc guidance
(Table 1); out of the ﬁrst 67 test orders, data for 52 chemicals have
been submitted to EPA. We have collected data for control groups
from approximately half of those submitted to the agency. Our
purpose in doing so was to gather information in support of a crit-
ical review of the EDSP ESB. One focus of that review was to quan-
tify the normal biological ranges for key endpoints that had
insufﬁcient historical databases when the test guidelines were
written. Without knowledge of the magnitude of endpoint vari-
ances, a reliable weight-of-evidence determination will be difﬁcult,
especially if only 1 or 2 signiﬁcant differences are observed across
the battery. A second focus of the review was on the appropriate-
ness of performance criteria deﬁned in the test guidelines and the
potential to revise and improve them. Finally, we examined the
impact of methodological differences between laboratories on
assay and endpoint variances. It must be emphasized that because
the review was restricted to a subset of the List 1 control data, our
analyses serve only as examples to underscore the importance of a
detailed, rigorous, and comprehensive evaluation of the perfor-
mance of the battery.2. Methods
Efforts to validate EDSP ESB assays have proven to be difﬁcult
and time-consuming (Borgert et al., 2011b). Prior to the comple-
tion of List 1 studies, data were insufﬁcient to conduct robust per-
formance evaluations of many of the screens. Our approach sought
to leverage data generated by companies complying with List 1 test
orders in an experiential manner to more thoroughly evaluate crit-
ical parameters that reﬂect assay performance and biological vari-
ance. It is beyond the scope of the paper to summarize in detail
each of these assays, but a general overview is provided below.
Complete information is provided by EPA at: http://www.epa.-
gov/ocspp/pubs/frs/publications/Test_Guidelines/series890.htm.Table 1
EPA’s EDSP Tier 1 Endocrine Screening Battery.
Test guideline Control datasets
In vitro screens
Estrogen Receptor (ER) Binding Assay 890.1250 13
ER Transcriptional Activation Assay 890.1300 15
Androgen Receptor Binding Assay 890.1150 16
Aromatase Assay 890.1200 23
Steroidogenesis Assay 890.1550 17
In vivo screens
Uterotrophic Assay 890.1600 26
Hershberger Assay 890.1400 21
Male Pubertal Assay 890.1500 25
Female Pubertal Assay 890.1450 25
Fish Short-Term Reproductive Assay 890.1350 22
Amphibian Metamorphosis Assay 890.1100 33
 Test Guidelines can be accessed at: http://www.epa.gov/ocspp/pubs/frs/publica-
tions/Test_Guidelines/series890.htm.2.1. Assay summary and purpose
2.1.1. In vitro screens
2.1.1.1. Estrogen Receptor (ER) Binding Assay. The ER Binding Assay
responds to chemicals that interact with the estrogen receptor. The
assay measures the receptor-binding afﬁnity of a chemical by
evaluating its ability to displace the endogenous hormone
17b-estradiol, which is prepared from rat uterine cytosol.
Substances that bind the estrogen receptor in rats are presumed
to be capable of binding the estrogen receptor in humans because
the binding domain of the receptor is highly conserved across spe-
cies. Note that the assay does not discern whether a chemical will
potentially act as an agonist or antagonist.
2.1.1.2. Estrogen Receptor Transcriptional Activation (ERTA)
Assay. The ERTA Assay responds to chemicals that bind and acti-
vate the estrogen receptor. In the assay, estrogen enters the target
cell, binds the receptor, and activates a signaling pathway leading
to the production of a luciferase enzyme. The luciferase product is
measured by the addition of luciferin; this causes a light-emitting
reaction to occur. The amount of light emitted is proportional to
the potency of the estrogen. Consequently, this procedure can
measure the ability of a chemical to induce hERa-mediated trans-
activation of luciferase gene expression. This assay is speciﬁc for
potential agonist activity.
2.1.1.3. Androgen Receptor (AR) Binding Assay. The AR Binding Assay
responds to chemicals that interact with the androgen receptor.
The assay measures the receptor-binding afﬁnity of a chemical
by evaluating its ability to displace a bound reference androgen
isolated from rat ventral prostates. Substances that bind the andro-
gen receptor in rats are presumed to be capable of binding the
androgen receptor in humans because there is a high degree of
DNA sequence conservation in the receptor across mammalian
phylogenetic lines. The assay does not discern whether a chemical
will potentially act as an agonist or antagonist.
2.1.1.4. Aromatase Assay. The Aromatase Assay responds to chemi-
cals that inhibit the catalytic activity of the cytochrome P450
enzyme aromatase. The assay is conducted by incubating human
recombinant microsomes with multiple concentrations of the test
chemical, radio-labeled androstenedione, and a cofactor for a spec-
iﬁed period of time. The rate of tritiated water released during the
conversion of the androstenedione to estrone is measured and
used as an indicator of aromatase activity.
2.1.1.5. Steroidogenesis Assay. The Steroidogenesis Assay allows
direct measurement of hormone production, cell viability, and
cytotoxicity in the human H295R adrenocortical carcinoma cell
line. The assay is performed under standard culture conditions in
24-well plates. After an acclimation period of 24 h, the cells are
exposed to increasing concentrations of the test chemical in tripli-
cate for 48 h. After the period of exposure, the levels of testos-
terone and estradiol released by the cells are measured.
2.1.2. In vivo screens
2.1.2.1. Male Pubertal Assay. The Male Pubertal Assay responds to
chemicals with potential anti-thyroid, androgenic, and
anti-androgenic activity, as well as agents that alter pubertal
development through mechanisms that induce changes in gonado-
tropins, prolactin, or through alterations in hypothalamic function.
It can also respond non-speciﬁcally in ways that confound inter-
pretation of endocrine mechanisms (Marty et al., 2011). The assay
uses juvenile male rats that are exposed to the test chemical daily
by oral gavage from post-natal day (PND) 23 through 53. This dura-
tion of treatment is needed to detect potential changes in pubertal
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age at preputial separation (PPS), a marker of pubertal develop-
ment in the male, changes in weights of accessory sex glands
[testes, epipidymides, ventral prostate, levator ani/bulbocaver-
nosus muscle (LABC), seminal vesicle with coagulating gland,
(SVCG)], changes in weights of the pituitary, liver, adrenals, kid-
neys, thyroid, and hormone concentrations [thyroxine (T4), TSH
(thyroid stimulating hormone), and testosterone].
2.1.2.2. Female Pubertal Assay. The Female Pubertal Assay responds
to chemicals with potential anti-thyroid, estrogenic, and
anti-estrogenic activity, as well as agents that alter pubertal devel-
opment through mechanisms that induce changes in luteinizing
hormone, follicle stimulating hormone, prolactin, or through alter-
ations in hypothalamic function. As seen with the Male Pubertal
Assay, it can also respond non-speciﬁcally in ways that confound
interpretation of endocrine mechanisms (Marty et al., 2011). The
assay uses juvenile female rats that are exposed to the test chem-
ical daily by oral gavage from PND 22 through 42. This duration of
treatment is needed to detect potential changes in pubertal devel-
opment and effects on the thyroid gland. The assay evaluates age at
Vaginal Opening (VO), a marker of pubertal development in the
female, changes in weights of uterus, ovaries, pituitary, liver, adre-
nal, kidneys, and thyroid, as well as changes in hormone concen-
trations (T4, TSH), and estrous cyclicity.
2.1.2.3. Amphibian Metamorphosis Assay (AMA). The Amphibian
Metamorphosis Assay assesses growth and developmental end-
points as well as thyroid histopathology of African clawed frog
(Xenopus laevis) tadpoles in response to test chemicals delivered
via the water. The rate of tadpole metamorphosis is controlled, in
part, by the Hypothalamus–Pituitary–Thyroid (HPT) axis. Thus,
the AMA assesses chemicals for the potential to interfere with
the normal function of the HPT axis. The assay represents a gener-
alized model to the extent that it is based on the conserved struc-
tures and functions of the HPT axis in vertebrates. The AMA is the
only assay in the EDSP ESB that detects potential effects on the thy-
roid gland in an animal undergoing morphological development.
2.1.2.4. Fish Short-Term Reproductive Assay (FSTRA). The Fish
Short-Term Reproductive Assay responds to chemicals that may
interfere with the normal function of the Hypothalamus–Pituitar
y–Gonadal (HPG) axis. The assay uses sexually mature fathead
minnow (Pimephales promelas) to detect changes in spawning,
morphology, gonadal histopathology, and speciﬁc biochemical
endpoints that reﬂect disturbances in the HPG axis. The FSTRA rep-
resents a generalized model to the extent that it as based on the
conserved structures and functions of the HPG axis in vertebrates.
2.1.2.5. Uterotrophic Assay. The Uterotrophic Assay responds to
chemicals with estrogenic activity. The assay utilizes either an ani-
mal model in which the HPT axis is not functional (immature) or an
ovariectomized model, leading to low baseline uterine weights and
low levels of endogenous estrogen. Uterineweights (with andwith-
out uterine ﬂuids) of animals exposed to the test chemical are com-
pared to a vehicle control group; a statistically-signiﬁcant increase
in uterine weights (wet or blotted) indicates a positive response. In
addition, a positive control group, administered ethinyl estradiol, is
included in the assay.
2.1.2.6. Hershberger Assay. The Hershberger Assay identiﬁes chem-
icals with androgenic or anti-androgenic activity. The assay uses
castrated male rats and measures the weights of ﬁve
androgen-dependent tissues (Cowper’s Gland, LABC, ventral
prostate, SVGC, and glans penis) to determine the potential
for androgen agonists, antagonists, and 5a-reductase inhibitors.A positive result in the agonist assay is a statistically-signiﬁcant
increase in 2 or more of the androgen-dependent tissues
compared to the vehicle control group. A positive result in
the antagonist assay is a statistically-signiﬁcant decrease in 2 or
more of the androgen-dependent tissues compared to the
control group (administered vehicle control plus testosterone
propionate (TP, 0.2 or 0.4 mg/kg). Positive controls are utilized in
both the agonist (vehicle control + TP) and antagonist assay
(TP + ﬂutamide).2.2. Analysis
Access to a subset of the control data was obtained from com-
panies complying with List 1 test orders. The number of datasets,
by assay, is shown in Table 1. Prior to analysis, all test chemical ref-
erence names were removed and several parameters were coded,
including the submitter, laboratory that performed the assay, com-
pany name, microsome source (if unique), non-standard reference
chemicals, and non-standard solvents. In addition, datasets were
made uniform by standardizing units.
The ﬁrst focus of the analysis was to quantify the normal biolog-
ical ranges for required endpoints in each assay. To do so, summary
statistics (overall mean, standard deviation, coefﬁcient of variation
[CV], and minimum and maximum raw values) were calculated for
each endpoint across studies. The second focus of the analysis was
on the appropriateness of performance criteria and the potential to
improve them with the evaluation of data from a large number of
studies. The EDSP ESB test guidelines (see Table 1) include perfor-
mance criteria for control data, which laboratories should meet to
conﬁrm that the assays were conducted properly. Fitted curve
parameters, mean values and CVs must fall within the deﬁned
ranges for the assay results to be considered fully acceptable. The
number and percentage of studies failing these criteria were tabu-
lated for each assay. The ﬁnal focus of the analysis was on the
impact of methodological differences between laboratories on end-
point variances and whether performance violations were systemic
(observable across laboratories) or driven by a minority of partici-
pating laboratories. Mean ranges and average and maximum vari-
ances and CVs (where appropriate) were calculated for each
endpoint. The following linear model was ﬁt to evaluate the impact
of laboratory on endpoint variance:yij ¼ lþ li þ eij ð1Þwhere yij is the observed coefﬁcient of variation for the jth study
conducted by the ith laboratory; l is the overall mean; li is the ﬁxed
effect of the ith laboratory; eij is the residual error.
The MIXED PROCEDURE in SAS (SAS, 2012) was used to ﬁt
model (1) separately for each endpoint with at least 25% of studies
in violation of the maximum CV or had CVs averaged across studies
that exceeded the maximum CVs allowed by the test guidelines.
Note the analysis was weighted to account for the different num-
bers of studies submitted by each laboratory.3. Results
For clarity and ease of presentation, this section has been orga-
nized by assay. Endpoint names are presented in italicized font.
Space for tables in the main text has been reserved for reporting
the number and percentage of studies failing the performance cri-
teria. All summary statistics for the analysis of the List 1 control
data can be found in the Supplementary material.
Table 3
Performance criteria in the ERTA.
Criterion Tolerance limit(s) Number of runs Number (%) failed
17b-Estradiol
log(PC50) 11.4 to 10.1 37 1 (3%)
log(PC10) <11 37 0 (0%)
log(EC50) 11.3 to 10.1 37 1 (3%)
Hill Slope 0.7–1.5 37 6 (16%)
17a-Estradiol
log(PC50) 9.6 to 8.1 37 0 (0%)
log(PC10) 10.7 to 9.3 37 0 (0%)
log(EC50) 9.6 to 8.4 37 1 (3%)
Hill Slope 0.9–2.0 37 10 (27%)
17a-Methyltestosterone
log(PC50) 6.0 to 5.1 21 13 (62%)
log(PC10) 8.0 to 6.2 33 22 (67%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1300 for a full listing of performance requirements. Abbreviations:
PC10 = 10 percent of control; PC50 = 50 percent of control; EC50 = half maximal
response.
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3.1.1. Estrogen Receptor (ER) Binding Assay
The ER Binding Assay uses 17b-estradiol and norethynodrel as
strong and weak positive controls, respectively. Non-linear regres-
sion methods are used to ﬁt curves (separately for the strong pos-
itive control, weak positive control, and test chemical) to a
modiﬁed version of the Hill Equation (Hill, 1910). Fitted curve
parameters, which include percent binding at the top and bottom
of the curve, an estimate of the Hill Slope, and the natural loga-
rithm of the residual standard deviation, must fall within deﬁned
tolerance limits for the assay results to be considered fully accept-
able. The number and percentage of studies failing these criteria
are presented in Table 2. Summary statistics are provided in
Tables A1 and A2. Of the thirteen studies that reported estimates
of 17b-estradiol ﬁtted curve parameters, two (15%) had a least
one tolerance limit violation. In addition, six studies (46%) reported
at least one parameter estimate for norethynodrel outside of its
acceptable range. Three studies (23%) were in violation of the tol-
erance limit for Bottom (% Binding), while four studies (31%) failed
the criterion for Hill Slope (log10(M)1).
3.1.2. Estrogen Receptor Transcriptional Activation (ERTA) Assay
The ERTA Assay uses 17b-estradiol, 17a-estradiol, and
17a-methyltestosterone as a strong agonist, weak agonist, and
very weak agonist, respectively. Non-linear regression methods
are used to ﬁt curves (separately for the strong agonist, weak ago-
nist, very weak agonist, and test chemical) to Hill’s Logistic
Equation (Hill, 1910). Fitted curve parameters include estimates
of the Hill Slope and concentration that provokes a response mid-
way between the baseline and maximum responses (EC50). These
parameters, along with calculations of 10 and 50 percent of control
(PC) values, must fall within deﬁned tolerance limits for the assay
results to be considered fully acceptable. The number and percent-
age of studies failing these criteria are presented in Table 3.
Summary statistics are provided in Tables A3 and A4. A majority
(62% and 67%) of ﬁtted curve parameters failed to fall within the
tolerance limits for the very weak agonist. In addition, the ranges
of acceptable values for Hill Slope (log10(M)1) were problematic
for the strong agonist and weak agonist.
3.1.3. Androgen Receptor (AR) Binding Assay
The AR Binding Assay uses methyltrienolone (R1881) and dex-
amethasone as strong and weak positive controls, respectively.
Non-linear regression methods are used to ﬁt curves (for the strongTable 2
Performance criteria in the Estrogen Receptor Binding Assay.
Criterion Tolerance
limit(s)
Number of
runs
Number (%)
failed
Radioinert 17b-estradiol ﬁtted curve parameters
loge(Residual Std.
Dev.)
62.35 18 0 (0%)
Top (% Binding) 94–111 19 1 (5%)
Bottom (% Binding) 4 to 1 19 1 (5%)
Hill Slope
(log10(M)1)
1.1 to 0.7 19 1 (5%)
Weak positive control (norethynodrel) ﬁtted curve parameters
loge(Residual Std.
Dev.)
62.35 18 0 (0%)
Top (% Binding) 94–111 19 0 (0%)
Bottom (% Binding) 4 to 1 19 3 (16%)
Hill Slope
(log10(M)1)
1.1 to 0.7 19 4 (21%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1250 for a full listing of performance requirements.
n = 13 studies, 1–3 runs reported per study.positive control, weak positive control, and test chemical, sepa-
rately) to a modiﬁed version of the Hill Equation (Hill, 1910).
Fitted curve parameters, which include percent binding at the
top and bottom of the curve, and an estimate of the Hill Slope,
must fall within deﬁned tolerance limits for the assay results to
be considered fully acceptable. The number and percentage of
studies failing these criteria are presented in Table 4. Summary
statistics are provided in Tables A5 and A6. All ﬁtted curve param-
eters were within the tolerance limits for the weak positive con-
trol. A single run was in violation of the tolerance limit for Hill
Slope (log10(M)
1) for R1881. No other violations were observed.3.1.4. Aromatase Assay
The Aromatase Assay uses 4-hydroxyandrostenedione (4-OH
ASDN) as a positive control. Non-linear regression methods are
used to ﬁt curves (for the positive control and test chemical, sepa-
rately) to a modiﬁed version of the Hill Equation (Hill, 1910). Fitted
curve parameters, which include percent binding at the top and
bottom of the curve, an estimate of the slope, and an estimate of
the concentration corresponding to 50% of control activity (IC50),
must fall within deﬁned tolerance limits for the assay results to
be considered fully acceptable. In addition, performance guidelines
have been deﬁned for the mean aromatase activity in the absence
of an inhibitor and the mean background control activity. The
number and percentage of studies failing these criteria are pre-
sented in Table 5. Summary statistics are provided in Tables A7
and A8. A majority (17 out of 23; 74%) of studies had at least 1
run in violation of the tolerance limits for the ﬁtted curveTable 4
Performance criteria in the Androgen Receptor Binding Assay.
Criterion Tolerance
limit(s)
Number of
runs
Number (%)
failed
R1881 ﬁtted curve parameters
Top (% Binding) 82–114 34 0 (0%)
Bottom (% Binding) 2.0 to 2.0 34 0 (0%)
Hill Slope
(log10(M)1)
1.2 to 0.8 34 1 (3%)
Weak positive control (dexamethasone) ﬁtted curve parameters
Top (% Binding) 87–106 34 0 (0%)
Bottom (% Binding) 12 to 12 34 0 (0%)
Hill Slope
(log10(M)1)
1.4 to 0.6 34 0 (0%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1150 for a full listing of performance requirements.
Table 5
Performance criteria in the Aromatase Assay.
Criterion Tolerance
limit(s)
Number
of runs
Number
(%) failed
4-OH ASDN ﬁtted curve parameter
Slope 1.2 to 0.8 67 3 (4%)
Top (%) 90–110 67 10 (15%)
Bottom (%) 5 to 6 67 3 (4%)
log(IC50) 7.3 to 7.0 67 17 (25%)
Minimum aromatase activity
(nmol/mg-protein/min)
P0.1 nmol/mg
protein/min
61 2 (3%)
Background control activity
(nmol/mg-protein/min)
615% of full
activity control
48 2 (4%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1200 for a full listing of performance requirements. Abbreviations: 4-
OH ASDN = 4-hydroxy androstenedione; IC50 = concentration corresponding to 50%
of control.
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lation of the tolerance limits and 1 study had at least 5 violations.
Two parameters were responsible for most of the violations: 15%
and 25% of all runs failed the criteria for Top (%) and log(IC50),
respectively.Table 7
Performance criteria in the Male Pubertal Assay.
Endpoint Acceptable
mean
range
Number (%)
of studies
failed
Maximum
CV (%)
Number (%)
of studies
failed
Age (PND) at 39.78– 1 (4%) 5.67 9 (36%)3.1.5. Steroidogenesis Assay
The Steroidogenesis Assay utilizes a known inducer (Forskolin)
and known inhibitor (Prochloraz) to determine if expected changes
in hormone production are detectable. Levels of testosterone and
estradiol must fall within deﬁned ranges for the assay results to
be considered fully acceptable. The number and percentage of
studies failing these criteria are presented in Table 6. Summary
statistics are provided in Tables A9 and A10. Nearly half (41%) of
all runs violated the acceptable level of Estradiol production for
the positive control inhibitor. One-quarter (25%) of runs reported
basal production of Estradiol below the acceptable minimum of
40 pg/mL. For all other measures, hormone production was within
acceptable levels at least 96% of the time.preputial
separation
46.51
Body weight (g)
at preputial
separation
188.28–
256.19
2 (8%) 7.57 22 (88%)
Initial body
weight (g)
45.47–
59.81
9 (36%) 10.25 2 (8%)
Final body weight
(g)
259.24–
332.06
0 (0%) 7.47 14 (56%)
SVCG w/ﬂuid (g) 0.295–
0.719
3 (12%) 21.06 15 (60%)
Ventral prostate 0.160– 0 (0%) 22.32 5 (20%)3.2. In vivo screens
3.2.1. Male Pubertal Assay
The Male Pubertal Assay utilizes a vehicle control as a compara-
tor to the test chemical. Performance criteria have been established
for a number of endpoints; these criteria are intended to indicate
whether the assay was sufﬁciently sensitive to allow conclusions
on whether the test chemical did, or did not, affect pubertalTable 6
Performance criteria in the Steroidogenesis Assay.
Criterion Tolerance limit(s) Number of
runs
Number (%)
failed
Minimum basal production
Testosterone P500 pg/mL 16 0 (0%)
Estradiol P40 pg/mL 16 4 (25%)
Induction (10 lM Forskolin)
Testosterone P1.5-fold solvent
control
47 1 (2%)
Estradiol P7.5-fold solvent
control
47 0 (0%)
Inhibition (1 lM Prochloraz)
Testosterone 60.5-fold solvent
control
46 0 (0%)
Estradiol 60.5-fold solvent
control
37 15 (41%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1550 for a full listing of performance requirements.development and growth. The number and percentage of studies
failing the performance criteria deﬁned in the test guidelines are
presented in Table 7. Developmental and growth endpoints are
summarized in Tables A11 and A12. All (25 out of 25) studies
had at least 1 mean-range violation and at least 1 CV violation.
In addition, 9 (36%) studies had at least 3 mean-range violations
and 21 (84%) had at least 3 CV violations. Finally, 1 (4%) study
had at least 5 mean-range violations and 8 (32%) had at least 5
CV violations.
Several endpoints, including Body Weight (g) at Preputial
Separation, Final Body Weight (g), Seminal Vesicle + Coagulating
Gland (SVCG) w/Fluid (g), Epididymis, left (g), and Epididymis, right
(g), had CVs averaged across studies that exceeded the maximum
CVs allowed by the test guidelines (Tables 7 and A12). The overall
mean of Kidneys (g), reported as 2.09 g in Table A11, was outside of
the acceptable mean range of 2.42–3.05 g (Table 7), and 76% of
studies fell outside of the acceptable range. One study was outside
the acceptable mean range for Age (PND) at Preputial Separation and
2 studies were outside the acceptable range for Body Weight (g) at
Preputial Separation. More importantly, 9 (36%) studies exceeded
the maximum CV for Age (PND) at Preputial Separation and 22
(88%) studies exceeded the maximum CV for Body Weight (g) at
Preputial Separation. In addition, 9 (36%) studies failed the mean
range for Serum TSH and 7 studies (28%) failed the CV criterion.
Model (1) was ﬁtted to endpoints with at least 25% of studies in
violation of the maximum CV or had CVs averaged across studies
that exceeded the maximum CVs allowed by the test guidelines.
Eight endpoints (Table 8) met one or both of these criteria. Based
on the overall F-tests, there were no statistically-signiﬁcant(g) 0.332
LABC (g) 0.447–
0.855
2 (8%) 27.10 2 (8%)
Epididymis (g) 0.364–
0.528
4 (16%) 16.39 2 (8%)
Liver (g) 9.99–15.35 0 (0%) 14.93 4 (16%)
Kidneys (g) 2.42–3.05 19 (76%) 14.76 1 (4%)
Pituitary (mg) 7.81–12.90 0 (0%) 15.98 7 (28%)
Adrenals (mg) 31.84–
61.11
0 (0%) 22.77 1 (4%)
Thyroid (mg) 14.00–
26.00
11 (44%) 23.63 3 (12%)
Serum T4 (ug/dL) 4.06–7.38 3 (12%) 27.46 1 (4%)
Serum
testosterone
(ng/mL)
0.260–
3.960
0 (0%) 89.70 1 (4%)
Serum TSH (ng/
mL)
4.21–24.11 9 (36%) 58.29 7 (28%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1500 for a full listing of performance requirements. Abbreviations:
CV = coefﬁcient of variation; PND = post-natal day; SVCG = seminal vesi-
cles + coagulating gland; LABC = levator ani/bulbocavernosus muscle;
T4 = thyroxine; TSH = thyroid stimulating hormone. n = 25 studies.
Table 8
Overall F-tests (One-Way Analysis of Variance) of the effect of laboratory on endpoint
variance. Results reported for endpoints with at least 25% of studies in violation of the
maximum CV.
Endpoint Numerator
DF
Denominator
DF
F-
value
PR > F
Male Pubertal Assay
Age (PND) at preputial
separation
4 20 2.05 0.1253
Body weight (g) at preputial
separation
4 20 0.68 0.6126
Final body weight (g) 4 20 2.83 0.0520
SVCG w/ﬂuid (g) 4 20 1.34 0.2904
Epididymis, left (g) 4 20 1.27 0.3156
Epididymis, right (g) 4 20 1.67 0.1966
Pituitary (mg) 4 20 1.26 0.3182
Serum TSH (ng/mL) 4 20 0.96 0.4502
Female Pubertal Assay
Age (PND) at vaginal
opening
4 20 0.27 0.8928
Liver (g) 4 20 1.48 0.2455
Fish Short-Term Reproductive Assay
Fertilization success (%) 2 19 0.06 0.9405
Abbreviations: DF = degrees of freedom; PND = postnatal day; SVCG = seminal vesi-
cles + coagulating gland; TSH = thyroid stimulating hormone.
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that the maximum allowable CVs deﬁned in the test guidelines
warrant further examination.
3.2.2. Female Pubertal Assay
The Female Pubertal Assay utilizes a vehicle control as a com-
parator to the test chemical. As seen with the Male Pubertal
Assay, performance criteria have been established for a number
of pubertal development and growth endpoints. The number and
percentage of studies failing these criteria are presented in
Table 9. Summary statistics are provided in Tables A13 and A14.
A majority (19 out of 25; 76%) of studies had at least 1
mean-range violation and 16 (64%) had at least 1 CV violation. In
addition, 1 (4%) study had at least 3 mean-range violations and 2
(8%) had at least 3 CV violations. The overall mean of AdrenalsTable 9
Performance criteria in the Female Pubertal Assay.
Endpoint Acceptable
mean range
Number (%)
of studies
failed
Maximum
CV (%)
Number (%)
of studies
failed
Age (PND) at
vaginal
opening
30.67–35.62 3 (12%) 6.52 6 (24%)
Body weight (g)
at vaginal
opening
101.71–
131.44
1 (4%) 13.94 1 (4%)
Final body
weight (g)
104.86–
204.55
0 (0%) 8.93 5 (20%)
Liver (g) 4.32–11.78 0 (0%) 13.13 8 (32%)
Kidneys (g) 0.95–2.20 0 (0%) 10.76 4 (16%)
Pituitary (mg) 5.86–12.08 0 (0%) 26.97 0 (0%)
Adrenals (mg) 38.34–48.84 19 (76%) 22.97 1 (4%)
Ovaries (mg) 36.54–
114.77
0 (0%) 23.20 3 (12%)
Uterus, blotted
(mg)
187.40–
410.38
0 (0%) 37.73 0 (0%)
Thyroid (mg) 6.20–22.20 0 (0%) 38.58 0 (0%)
Serum T4 (ug/
dL)
2.69–5.38 0 (0%) 29.39 1 (4%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1450 for a full listing of performance requirements. Abbreviations:
CV = coefﬁcient of variation; PND = postnatal day; TSH = thyroid stimulating hor-
mone. n = 25 studies.(mg), reported as 36.07 mg in Table A13, was outside of the accept-
able mean range of 38.34–48.84 mg (Table 9). Three (12%) studies
were outside the acceptable mean range for Age (PND) at Vaginal
Opening, while 6 (24%) failed to meet the criterion for maximum
CV. Model (1) was ﬁtted to endpoints with at least 25% of studies
in violation of the maximum CV. Two endpoints (Table 8) met this
criterion. Based on the overall F-tests, there were no
statistically-signiﬁcant differences between laboratories at the
a = 0.05 level, suggesting, similar to the Male Pubertal Assay, that
the maximum allowable CVs deﬁned in the test guidelines warrant
further examination.
3.2.3. Amphibian Metamorphosis Assay
Developmental and growth endpoints in the Amphibian
Metamorphosis Assay are summarized in Tables A15 and A16.
The number and percentage of studies failing the performance cri-
teria deﬁned in the test guidelines are presented in Table 10. Of the
25 studies that reported information on tadpole survival, 1 (4%)
failed the performance criterion for control mortality. Of the 33
studies reporting developmental data, none failed the performance
criterion for median Nieuwkoop and Faber (1994; NF) Stage on day
21 and 1 (3.03%) failed the criterion for NF Stage distribution at test
termination.
3.2.4. Fish Short-Term Reproductive Assay
Growth endpoints and a summary of survival and reproduction
in the Fish-Short Term Reproductive Assay are presented in Tables
A17, A18, and A19. The number and percentage of studies failing
the performance criteria deﬁned in the test guidelines are pre-
sented in Table 11. Twenty-two studies reported information on
survival and reproduction; 1 study (4.55%) failed the performance
criterion for control mortality; 1 study (4.55%) failed the perfor-
mance criterion for egg production, and 7 (31.82%) studies failed
the performance criterion for fertilization success. At test termina-
tion, mean values for Female Body Weight (g) andMale Body Weight
(g) ranged from 1.05–1.92 to 2.00–4.74, respectively. Also at test
termination, mean values for Female Body Length (mm) and Male
Body Length (mm) ranged from 1.05–1.92 to 2.00–4.74, respec-
tively. Model (1) was ﬁtted to endpoints with at least 25% of stud-
ies in violation of the maximum CV. Two endpoints (Table 8) met
this criterion. Based on the overall F-test, there was no
statistically-signiﬁcant difference between laboratories at the
a = 0.05 level.
3.2.5. Uterotrophic Assay
Developmental and growth endpoints in the Uterotrophic Assay
are summarized in Tables A20 and A21. The number and percent-
age of studies failing the performance criteria deﬁned in the test
guidelines are presented in Table 12. Three alternative assay
designs were utilized by respondents providing access to control
data: the immature model using oral gavage as the route of admin-
istration; the ovariectomized model using subcutaneous injection;Table 10
Performance criteria in the Amphibian Metamorphosis Assay.
Endpoint Acceptable values No. of
studies
No. (%)
failed
Control
mortality
62 Tadpoles/replicate 25 1 (4.00%)
NF stage, day
21
Median NF stageP 57 33 0 (0.00%)
NF stage, day
21
90th–10th percentiles < 4
stages
33 1 (3.03%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1100 for a full listing of performance requirements. Abbreviations:
NF = Nieuwkoop and Faber (1994; NF) developmental stage.
Table 11
Performance criteria in the Fish Short-Term Reproductive Assay.
Endpoint Acceptable values No. of
studies
No. (%)
failed
Survival (%) P90% 22 1 (4.55%)
Eggs/female/day P15 Eggs/female/day in all
replicates
22 1 (4.55%)
Fertilization
success (%)
P95% 22 7 (31.82%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1350 for a full listing of performance requirements.
Table 13
Performance criteria in the Hershberger Assay.
Endpoint Maximum CV (%) No. of studies No. (%) faileda
Androgenic (vehicle control)
Seminal vesicles (mg) 40 21 2 (9.52%)
Ventral prostate (mg) 45 21 4 (19.05%)
LABC (mg) 30 21 1 (4.76%)
Cowpers glands (mg) 55 21 1 (4.76%)
Glans penis (mg) 22 21 2 (9.52%)
Anti-androgenic (vehicle control + 0.4 mg/kg TP)
Seminal vesicles (mg) 40 20 0 (0.00%)
Ventral prostate (mg) 40 20 2 (10.00%)
LABC (mg) 20 20 1 (5.00%)
Cowpers glands (mg) 35 20 0 (0.00%)
Glans penis (mg) 17 20 1 (5.00%)
Anti-androgenic (vehicle control + 0.2 mg/kg TP)
Seminal vesicles (mg) 40 1 0 (0.00%)
Ventral prostate (mg) 40 1 0 (0.00%)
LABC (mg) 20 1 0 (0.00%)
Cowpers glands (mg) 35 1 0 (0.00%)
Glans penis (mg) 17 1 0 (0.00%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1400 for a full listing of performance requirements. Abbreviations:
CV = coefﬁcient of variation; LABC = levator ani/bulbocavernosus muscle;
TP = testosterone propionate.
a The test guidelines require no more than 3 tissues from both the vehicle control
and the high dose (data not provided) to exceed the maximum CV.
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are acceptable per the assay guidelines (OPPTS 890.1600). The only
performance criterion to be met for acceptability of the assays is
that the blotted uterine weight be less than 0.09% of body weight
for the immature model or less than 0.04% of body weight for
the ovariectomized model. As shown in Table 12, all studies met
the performance criterion for blotted uterine weights for both ani-
mal models (immature vs. ovariectomized) and routes of adminis-
tration (oral vs. subcutaneously).
3.2.6. Hershberger Assay
To meet the performance criteria for the Hershberger Assay, no
more than 3 of the 10 tissue weights may exceed the CV in the con-
trol group (agonist assay-vehicle control, antagoinst assay-vehicle
control + TP) and high dose tested. If 4 or more tissues exceed the
CV, the assay is to be repeated. The performance criteria estab-
lished for all 5 androgen dependent tissues and the number and
percentage of studies failing these criteria are presented in
Table 13. Developmental and growth endpoints are summarized
in Tables A22 and A23. Of the 21 studies that reported information
on the reference androgen agonist, 2 (9.5%) failed to meet the per-
formance criteria for Seminal Vesicles (mg) and Glans Penis (mg), 1
failed to meet the criteria for Levator Ani/Bulbocavernosus
Complex (LABC) (mg) and Cowpers Glands (mg), and 4 studies
(19%) failed the criterion for Ventral Prostate (mg). For
anti-androgenic activity (vehicle control with 0.4 mg/kg TP), 20
studies were reported and 2 (10%) failed to meet the performance
criterion for Ventral Prostate (mg). Due to the limitations of the data
presented in this manuscript, we could not evaluate whether the
high dose levels of the test chemicals from the submitted studies
also exceeded the speciﬁed CV, causing the studies to be repeated.4. Discussion
The EDSP Tier 1 Endocrine Screening Battery is intended to be a
suite of in vitro and in vivo assays to identify the potential of a
chemical to interact with the estrogen, androgen, thyroid, or
steroidogenesis systems. The initial set of List 1 chemicals provides
enough data to conduct a detailed, rigorous, and comprehensiveTable 12
Performance criteria in the Uterotrophic Assay.
Endpoint Performance
criterion
No. of
studies
No. (%)
failed
Blotted uterine weights
Immature model (oral gavage) <0.09% of body
weight
9 0 (0%)
Ovariectomized model
(subcutaneous)
<0.04% of body
weight
3 0 (0%)
Ovariectomized model (oral
gavage)
<0.04% of body
weight
14 0 (0%)
Note: Performance criteria based on control substances only. Refer to OCSPP Test
Guideline 890.1600 for a full listing of performance requirements.evaluation of the performance of the battery. Due to animal wel-
fare concerns and the signiﬁcant cost of running the screens (as
currently designed, $750,000–$1,000,000 per chemical [US EPA,
2008]), the SAB/SAP recommendation to stop and review all testing
methods is clearly sensible. What is unclear, however, is whether
EPA will have the opportunity to conduct this review prior to issu-
ance of List 2 test orders, as a 2009 House Appropriations
Committee report (H.R. 2996. H. Rept. 111–180) directed the
Agency to release a second list of no less than 100 chemicals for
ESB testing, which EPA published in November 2010 (Federal
Register, 2010).
The analysis of List 1 control data presented here, along with
concerns raised elsewhere (e.g., Borgert et al., 2011a,b), support
the notion that EPA should be given the opportunity to review all
testing methods before issuing test orders for the second list of
chemicals. Given the frequency with which certain performance
criteria were violated, one focus of that review should consider
adjustments to the tolerance limits for ﬁtted curve parameters,
acceptable mean ranges and maximum CVs to better reﬂect biolog-
ical variability. These performance criteria are intended to serve as
a benchmark for determining the quality of the data submitted to
EPA and also provide a way to judge the variability in each end-
point. Poorly-deﬁned criteria will result in discarded data and
wasted resources.
The Male Pubertal Assay highlights this concern clearly. During
the assay validation program (EPA, 2007a), all participating labora-
tories had CVs for certain endpoints that exceeded the maximum
allowed under the test guidelines. One laboratory failed 6 of 17 cri-
teria, two laboratories failed 5, and another laboratory failed 4.
Nonetheless, the criteria were not modiﬁed prior to List 1 test
orders being issued. These inter-laboratory validation results are
similar to the analysis presented here of a subset of the List 1 con-
trol data. All (25 out of 25) studies had at least 1 CV violation, 21
(84%) had at least 3 CV violations, and 8 (32%) had at least 5 CV vio-
lations. In addition, ﬁve endpoints (Body Weight (g) at Preputial
Separation, Final Body Weight (g), SVCG w/Fluid (g), Epididymis, left
(g), and Epididymis, right (g)) had CVs averaged across studies that
exceeded the maximum allowed by the test guidelines. The model
ﬁtting exercise demonstrated that the magnitudes of endpoint
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Performance violations were therefore systemic (observable across
laboratories, including those involved in the initial validation
effort), not driven by one or two laboratories, and thus, very unli-
kely to have been caused by poor execution.
Acceptable mean ranges were also problematic in the Male
Pubertal Assay. All studies had at least 1 mean-range violation, 9
(36%) studies had at least 3 mean-range violations, and 1 (4%)
study had at least 5 mean-range violations. In addition, mean
ranges reported in Table A12 tended to be wider than those
observed in the EPA inter-laboratory validation study. For example,
EPA reported a mean range of 39.50–43.92 days for Age (PND) at
Preputial Separation (EPA, 2007a). In the present data compilation
representing 25 assays, these mean values ranged from 43.18 to
48.00 days. Similarly, Body Weight (g) at Preputial Separation ranged
from 198.57 to 236.49 g in the EPA inter-laboratory validation
study, whereas these mean values ranged from 195.76 to
267.68 g in this analysis.
There are a number of factors which might contribute to the
disparity between endpoint variances observed in this study and
in the EPA inter-laboratory validation. These same factors might
also explain why many of the acceptable mean ranges are too nar-
row and why most of the maximum CVs are too small. EPA used
historical control data to set the performance criteria, which are
‘‘intended to cover 95% of the values likely to be encountered from
acceptable laboratories’’ (EPA, 2007a). It is unclear, however, how
much information was actually available for deﬁning these targets.
Based on comparisons between the current analysis (25 studies)
and EPA validation (4 studies), it is likely that the historical control
data provided an incomplete picture of natural variability.
Furthermore, permissible differences in study design and execu-
tion are certain to contribute to inter- and intra-laboratory vari-
ability. These differences include diet, housing, water source,
dosing vehicle, species and strain of rat, and daily gavage adminis-
tration, among others. Finally, one of the primary endpoints in the
Male Pubertal Assay is Age (PND) at Preputial Separation and, since
attainment of puberty is a subjective evaluation, inter- and
intra-laboratory variability is to be expected (Stump et al., 2014).
The Female Pubertal Assay also illustrates the problem of
poorly-deﬁned performance criteria. During the assay validation
program (EPA, 2007b), all participating laboratories had CVs for
certain endpoints that exceeded the maximum allowed under the
test guidelines. This inter-laboratory validation result is similar
to the analysis presented here. A majority (16 out of 25; 64%) of
studies had at least 1 CV violation and 2 (8%) had at least 3 CV vio-
lations. As seen in the Male Pubertal Assay, there was insufﬁcient
evidence to conclude that endpoint variances differed signiﬁcantly
between laboratories. Acceptable mean ranges were also problem-
atic: 19 out of 25 (76%) studies had at least 1 mean-range violation
and 1 (4%) study had at least 3 mean-range violations. Mean ranges
reported in Table A14 were consistently wider than those observed
in the EPA inter-laboratory validation study. EPA reported a mean
range of 31.56–34.21 days for Age (PND) at Vaginal Opening. Mean
values for this same endpoint ranged from 32.73 to 36.79 days in
the present study. Similarly, Body Weight (g) at Vaginal Opening
ranged from 109.67 to 119.84 g in the EPA inter-laboratory valida-
tion study, whereas these mean values ranged from 105.53 to
137.08 g in this analysis. Disparities were also seen in Kidneys (g)
(mean range 1.15–1.49 vs. 1.47–1.67), Adrenals (mg) (mean range
31.60–43.56 vs. 41.00–49.00), and Serum T4 (ug/dL) (mean range
2.97–5.04 vs. 4.77–7.94).
For the Female Pubertal Assay, the same factors mentioned
above likely contribute to the inconsistency between endpoint
variances observed in this study and in the EPA inter-laboratory
validation, as well as explain why many of the maximum CVs are
too small. The same permissible differences in study design andexecution also contribute to inter- and intra-laboratory variability.
The subjective evaluation of attainment of puberty (Age (PND) at
Vaginal Opening and Body Weight (g) at Vaginal Opening) is also a
source of variation.
Performance criteria were less problematic in the Amphibian
Metamorphosis Assay. Of the 25 studies that reported information
on tadpole survival, 1 (4%) failed the performance criterion for con-
trol mortality. Of the 33 studies reporting developmental data,
none failed the performance criterion for median NF Stage on
day 21 and 1 (3.03%) failed the criterion for NF Stage distribution
at test termination. Performance criteria were reasonably
well-deﬁned in the Fish Short-Term Reproductive Assay.
Twenty-two studies reported information on survival and repro-
duction; 1 study (4.55%) failed the performance criterion for con-
trol mortality; 1 study (4.55%) failed the performance criterion
for egg production, and 7 (31.82%) studies failed the performance
criterion for fertilization success.
Performance criteria for the Uterotrophic Assay were met in all
studies for both immature and ovariectomized models, and both
routes of administration. The extensive validation of the assay
(Kanno et at., 2001, 2003a,b; OECD, 2001; Owens et al., 2003) likely
contributes to the accurate performance criteria contained in the
guidelines. Performance criteria were reasonably well-deﬁned in
the Hershberger Assay. However, the maximum allowable CV for
Ventral Prostate (mg) was problematic, particularly for the agonist
assay. In addition, data were only available from a single
anti-androgenic study utilizing the 0.2 mg/kg/day dose of testos-
terone propionate. As such, results reported here should not be
viewed as a rigorous evaluation of the suitability of these criteria.
Lastly, performance criteria based on the CV must also be met by
the high-dose treatment group. Since this analysis was restricted
to control data, concerns remain about the variability in
androgen-dependent tissues exposed to treated doses being
greater than that found in the controls. This is a distinct possibility
and should be considered in a comprehensive evaluation of the
suitability of performance criteria.
Tolerance limits for ﬁtted curve parameters and hormone con-
centrations were problematic in many of the in vitro screens. For
instance, 31% of runs reported estimates of Hill Slope (log10(M)1)
for the weak positive control outside the tolerance limits in the
ER Binding Assay. An expansion of the lower limit from 1.1 to
1.3 would encompass all of the reported ﬁndings. A majority of
runs (62% and 67%) failed both performance criteria for the very
weak agonist (17a-methyltestosterone) in the ERTA Assay. In addi-
tion, the ranges of acceptable values for Hill Slope (log10(M)1)were
problematic for the strong agonist (17b-estradiol) and weak ago-
nist (17a-estradiol). In the Aromatase Assay, 25% of runs reported
unacceptable estimates of log(IC50) for the positive control; there
was approximately an equal number of values above and below
the acceptable range. A slight modiﬁcation of the lower limit from
7.3 to 7.4 would capture more than half of the out-of-range
estimates. In the Steroidogenesis Assay, 41% of runs reported unac-
ceptable levels of Estradiol production for the positive control inhi-
bitor (1 lM Prochloraz) and 25% of runs reported basal production
of Estradiol below the acceptable minimum.
The discussion devoted to performance criteria highlights an
important question that has not been addressed by EPA: when
does a violation(s) render a study unreliable? Although many of
the violations are minor (i.e., narrowly missing the acceptable
mean range or maximum CV), little to no guidance exists on the
degree to which assays need to be re-started for failing to meet
performance criteria. We recommend that a second focus of the
suggested EPA review of the EDSP ESB be to provide detailed,
assay-speciﬁc direction on when results should be discarded.
This point is in agreement with a FIFRA Scientiﬁc Advisory Panel
(SAP), which suggested that speciﬁc guidance be developed to
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unusable (FIFRA SAP, 2013). From our experience responding to
List 1 test orders, we are aware that many assays were re-started
due to concerns over missed performance criteria. Although the
overall incidence of assay re-starts is unknown, this undoubtedly
increased animal use and overall costs of the EDSP program and
contributed to delays. However, those expenditures were not
included in the estimated costs of the eleven EDSP ESB assays
(US EPA, 2009b). In order to more accurately estimate the costs
of the Tier 1 battery and to understand how best to reﬁne guidance
for re-starting assays, we encourage EPA to consult the laboratories
that conducted List 1 screening to determine the incidence that
assays were re-started and the associated costs in terms of animals,
resources, and time to complete the screening.
The FIFRA SAP also highlighted the frequency with which cer-
tain performance criteria were violated and discussed permissible
differences in study design and execution that are likely to con-
tribute to inter- and intra-laboratory variability (FIFRA SAP,
2013). Consistent with this dialogue, we recommend that a third
focus of the suggested EPA review of the EDSP ESB should be to
identify protocol differences with a large inﬂuence on endpoint
variance. After identiﬁcation of these inﬂuential factors, experi-
mental guidelines could be re-deﬁned such that endpoint vari-
ances are reduced and performance criteria are violated less
frequently.
A phased implementation of the EDSP should serve, over time, to
improve the speciﬁcity, sensitivity, and interpretability of the ESB
battery. At this time, EPA should review all List 1 control data sub-
mitted to the Agency (52 chemicals). Updating the performance cri-
teria and protocols based on such a reviewwould eliminatemany of
the violations that occurred from happening again with the second
list of chemicals. This, however, will have little or no beneﬁt if EPA is
not allowed to follow the SAB/SAP recommendation to complete
the review prior to issuing test orders for the second list of chemi-
cals. Indeed, if this decision is made, all beneﬁts of this and similar
efforts will go unrealized, including some beneﬁts of EPA’s
long-term effort to develop high-throughput methods for use in
the EDSP, an effort now known as ‘‘EDSP-21’’ (U.S. EPA, 2011b).
The EDSP-21 program is currently most well developed for the
estrogenic pathway, with a stated goal of eventually replacing the
Uterotrophic Assay in the Tier 1 battery in order to reduce animal
use and costs and increase the overall efﬁciency of the program.
However, the analyses presented here reveal that this particular
substitution is likely to affect the EDSP program opposite of what
was intended, for the following reason. Justiﬁably, EPA and others
agree that in principle, in vivo assays should be given more weight
than in vitro assays in the interpretation of the Tier 1 screening
results (Borgert et al., 2011a; US EPA, 2011a). Hence, replacing an
in vivo with in vitro assays would shift interpretational emphasis
to the other in vivo endpoints remaining in the battery. Because
the Tier 1 in vivo screens vary widely in meeting performance cri-
teria, as shown here, this particular substitution would shift inter-
pretational emphasis from the most reliable in vivo assay in the
battery (Uterotrophic) to the least reliable (Pubertal Assays).
Unless EPA is given the time and resources to fully evaluate perfor-
mance of the battery, it will be difﬁcult to make improvements to
the battery without incurring unforeseen liabilities.Conﬂict of Interest
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